two-component covid-19 vaccine (cho cell)
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
3
Phase 4
0
Earliest trial started Jun 18, 2021 (NCT04818801)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05398848 | Phase 3 | Sep 30, 2022 | Jiangsu Rec-Biotechnology Co., Ltd. |
| NCT05323435 | Phase 2/Phase 3 (Phase 3) | May 30, 2022 | AI Kuwait Hospital, Jiangsu Rec-Biotechnology Co., Ltd. |
| NCT05084989 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2021 | Government of China, Jiangsu Rec-Biotechnology Co., Ltd. |
| NCT04818801 | Early Phase 1 (Phase 1) | Jun 18, 2021 | IQVIA, Jiangsu Rec-Biotechnology Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Rec-Biotechnology Co., Ltd. | For profit | 4 | 4 | 2 | 2021 |
| AI Kuwait Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Government of China | Government | 1 | 0 | 1 | 2021 |
| IQVIA | For profit | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1